Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Skin Diseases, Papulosquamous 1 Skin Diseases 1 Psoriasis 1 Plaque, Amyloid 1 Lymphoma, Follicular 1 Bronchiolitis Obliterans Syndrome 1 Arthritis, Rheumatoid 1

Interventions

Methotrexate 8 Adalimumab 7 Etanercept 5 tocilizumab 4 Rituximab 4 tofacitinib 3 Abatacept 3 olokizumab 2 golimumab 2 Tumor Necrosis Factor Inhibitors 2 Antirheumatic Agents 2 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 baricitinib 1 andecaliximab 1 Vitamin D 1 Vaccines 1 TACI receptor-IgG Fc fragment fusion protein 1 Syringes 1 Sulfasalazine 1 Saline Solution 1 Leflunomide 1 Hydroxychloroquine 1 Herpes Zoster Vaccine 1 Folic Acid 1 Fish Oils 1 Fatty Acids, Omega-3 1 Eicosapentaenoic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Arthritis, Rheumatoid × baricitinib × Clear all

NCT01721044 2019-09-18

RA-BEACON

Eli Lilly and Company

Phase 3 Completed

527 enrolled 37 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡